The publications on TP53 mutation have focused on its expression in breast cancer and the contribution of its polymorphism, particularly codon 72 to breast cancer (28, 31, 33, 36, 92–94), as well as to its interaction with MDM2 344T>A polymorphism in response to chemotherapy of breast cancer in Tunisia (95). Here, TP53 is linked to breast carcinoma.